MedTrace Logo

Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

NCT00851955 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2016-01-12

No results posted yet for this study

Summary

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Massimo Raimondo, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-12-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851955 on ClinicalTrials.gov